Home
½ÃÀÛÆäÀÌÁö
Áö³È£º¸±â
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¸µ¶½Åû
Àüü±â»ç
UPDATE
: 2021.4.16 ±Ý 17:56
±â»ç°Ë»ö
Cover Story
¼øÈ¯±â
³»ºÐºñ
È£Èí±â
¼Òȱâ
½Å°æ°ú
Á¤½Å°Ç°
°¨¿°³»°ú
Sub Story
Interview
Drug Review
Conference Report
Late Breaking Studies
Research Gateway
Expert Opinion
»ó´Ü¿©¹é
񃯇
(Àüü 20°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
[Cover Story]
¾Ï ¿¹¹æ ¿°µÎ¿¡ µÐ ¼ÒȱâÁúȯ °ü¸®Àü·«
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 13:45
[Sub Story]
ÀÌÁ¤Ç¥¸¶´Ù PPI ÀÖ¾ú´Ù
ÀÌ»óµ· ±âÀÚ
2021-01-22 13:34
[Sub Story]
PPI¿¡ ÇÊÀûÇÏ´Â P-CABÀÇ µîÀå
THE MOST
2021-01-22 13:28
[Interview]
´õµò ÀÛ¿ë½Ã°£Àº PPIsÀÇ Å»ýÀû ÇѰè
ÀÌ»óµ· ±âÀÚ
2021-01-22 13:26
[Drug Review]
±¹»ê PPI º¹ÇÕÁ¦, ¼Ó¹æÇü esomeprazole
ÀÌ»óµ· ±âÀÚ
2021-01-22 13:22
¶óÀÎ
[Sub Story]
Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á Ç×»ýÁ¦¿¡¼ P-CAB±îÁö
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 13:15
[Sub Story]
¼ÒȺҷ®Áõ Áø´Ü ¶§ºÎÅÍ À§¾Ï ¿©ºÎÈ®ÀÎ °Á¶
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 12:00
[Interview]
¡°¼ÒȺҷ® ¾ÆÇü Áß½É Ä¡·áÀü·« Á¦½Ã¡±
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:56
[Sub Story]
C.difficile °íÀ§Ç豺¿¡ ÇÁ·Î¹ÙÀÌ¿Àƽ½º ±Ç°í
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:51
[Drug Review]
¡®±Ù°Å ±â¹Ý¡¯ ÇÁ·Î¹ÙÀÌ¿Àƽ½º·Î ³ª°¡´Â Áß
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:45
¶óÀÎ
[Sub Story]
¾Æ½ºÇǸ° + Ç×Ç÷¼ÒÆÇÁ¦ ¼Òȼº±Ë¾ç À§Çè¡è
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:38
[Sub Story]
DAA-µ¿¹ÝÁúȯ ¾àÁ¦ °£ »óÈ£ÀÛ¿ë °Á¶
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:33
[Sub Story]
À¯ÀüÀÚÇü¡¤Ä¡·áº´·Â¡¤°£°æº¯Áõ È®ÀÎ °Á¶
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:23
[Sub Story]
HBV ¾àÁ¦³»¼º¡¤ÀçȰ¼ºÈ °ü¸®¿¡ ¹«°Ô
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:18
[Conference Report]
°£¿° °ü¸®, °£¾Ï À§Çè °¨¼Ò·Î Á÷°á
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 11:04
¶óÀÎ
[Conference Report]
CÇü°£¿° Ä¡·áÅëÇÑ °£¾Ï À§Çè °¨¼Ò È®ÀÎ
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 10:57
[Interview]
¡°°íÀ§Çè CAD¿¡¼ ACEI ÀÔÁö È®ÀÎÇß´Ù¡±
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 10:53
[Drug Review]
´Ã¾î³ª´Â NSAIDs ¼Òȼº±Ë¾ç ¿¹¹æ ´ë¾È
ÀÓ¼¼Çü ±âÀÚ
2021-01-22 10:45
[Conference Report]
¸¸¼º BÇü°£¿° Ä¡·áÀü·« ¾÷µ¥ÀÌÆ®
THE MOST
2021-01-22 10:39
[Conference Report]
Áö¹æ°£ ¹× °£¼¶À¯ÈÁõ Ä¡·áÀü·«
THE MOST
2021-01-22 10:34
-
1
-
¿©¹é
Sub
news
MET + SGLT-2i 1Â÷ Ä¡·áÀü·«À¸·Î Á¦½Ã
´ç´¢º´ + CKD ÅëÇÕÀû °ü¸®KDIGO´Â ´ç...
µ¿¾Æ½Ã¾ÆÀο¡ Æ¯ÈµÈ Ç×Ç÷Àü Ä¡·áÀü·« ¾÷µ¥ÀÌÆ®
µ¿¾Æ½Ã¾Æ ÆÐ·¯µ¶½º µîÀå¹è°æ2012³â º»ÀÎÀÌ ...
¡°½ÉºÎÀü °ü¸®¿¡¼ SGLT-2¾ïÁ¦Á¦ ¿ªÇÒ Ä¿Áú °Í¡±
Q. ±¹³» ½ÉºÎÀü À¯º´·üÀÇ º¯ÈÃßÀ̰¡ ±Ã±ÝÇÏ...
¿©¹é
¿©¹é
Back to Top